This has been flagged in the recent Shareholder Update, Orbital is an excellent technology/device for Bronchitol, but no long useful for the company since the drug is sold.
Someone may question if it's sold cheap for only US$5m, considering the current cash position adding another AU$7.5m into the bank account will extend the cash runway for at least 1-2 quarters.
Positive.
Ann: Aptar Pharma Pays PXS Us$5m to Acquire Orbital Technology, page-4
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
